MARLBOROUGH, Mass., Sept. 17, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Silk Road Medical, Inc. (Nasdaq: SILK), a medical device company that pioneered a new approach for stroke prevention and the treatment of carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). "Completing this acquisition enables Boston Scientific to strengthen our vascular technology solutions by bringing the ...

NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Silk Road Medical, Inc. (Nasdaq: SILK), relating to its proposed merger with Boston Scientific Corporation and Seminole Merger Sub. Under the terms of the agreement, Silk Road stockholders wi ...

MONSEY, N.Y., Aug. 19, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP has renewed its investigation into the fairness of the proposed sale of Silk Road Medical, Inc. (Nasdaq: SILK) ("SILK") to Boston Scientific Corporation for $27.50 per share in cash. On July 29, 2024, SILK filed a definitive proxy concerning the proposed sale with the SEC. Based on our review of the proxy, we have renewed our investigation into whether there are any undisclosed potential conflicts of interest. If you remain ...

Silk Road Medical (SILK) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.38. This compares to loss of $0.35 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -10.53%. A quarter ago, it was expected that this medical device maker would post a loss of $0.40 per share when it actually produced a loss of $0.36, delivering a surprise of 10%. Over the last four quarters, the compa ...

产品组合 - 公司目前在美国市场销售TCAR产品组合,主要包括ENROUTE NPS、ENROUTE NPS PLUS和ENROUTE支架[125,126] 监管审批和市场准入 - 2023年1月,CMS启动了对20.7号国家承保决定的全国性覆盖分析,并于2023年10月11日发布了最终决定备忘录[127,128,129,130,131] - 公司正在积极推进在日本和中国的监管审批和市场准入工作[133] 销售和营销策略 - 公司将销售和营销重点放在血管外科医生群体,并与其他具有CEA或CAS经验的专科医生合作[132] 公司并购 - 公司与波士顿科学公司签订了合并协议,预计将于2024年下半年完成[135,136,137,138] 财务表现 - 公司收入主要来自TCAR产品的销售,受多种因素影响存在季节性波动[139,140] - 公司毛利率受多方面因素影响,预计未来将有所提升[141,142,143] - 收入增长13%至51.2百万美元,主要由于TCAR手术量增加以及销售区域扩张[152] - 毛利率增加至75%,主要受益于采购价格优惠、生产效率提高以及运输成本降低[153] - 研发费用增加10%至11.9百万美元,主要由于人员成本增加[153] - 销售及管理费用增加22%至43.8百万美元,主要由于收购相关费用增加以及销售团队扩张[154] 现金流和资金状况 - 现金、现金等价物和投资总额为186.2百万美元,有75.0百万美元的未偿还贷款本金[163] - 预计未来12个月内现有现金和预期收入可满足公司运营资金需求[169] - 经营活动现金流出18.7百万美元,主要由于净亏损和营运资金变动[171] - 投资活动现金流入8.1百万美元,筹资活动现金流入13.1百万美元[170] - 截至2024年6月30日,公司经营活动使用的现金净额为1680万美元,主要由于净亏损2990万美元和非现金支出1820万美元,部分被营运资产净变动510万美元所抵消[172] - 截至2024年6月30日,公司投资活动提供的现金净额为810万美元,主要由于投资到期收回12490万美元,部分被投资购买11550万美元和购买1.3百万美元的固定资产所抵消[173] - 截至2024年6月30日,公司筹资活动提供的现金净额为1310万美元,主要由于员工行权和ESPP计划收到的款项[175] - 公司预计将因与Boston Scientific的合并而产生额外负债,主要为与交易完成挂钩的费用[177] 会计政策和风险管理 - 公司的关键会计政策和估计在2024年6月30日的三个月和六个月内未发生重大变化[179] - 公司现金、现金等价物和投资总额为1.862亿美元,主要投资于银行存款、货币市场基金、美国国债、公司债券等[183] - 公司面临利率风险,主要来自于可变利率的贷款,利率上限为7.50%[185,186] - 公司面临信用风险,主要来自于现金和现金等价物存放在银行,以及应收账款[187,188,190] - 公司面临通胀风险,预计未来成本将持续上升,可能无法完全通过价格上涨来抵消[192] 研发投入 - 公司持续加大研发投入,用于新产品开发和临床研究等[144]

财务表现 - 第二季度收入为5,124万美元，同比增长13%[4] - 毛利润为3,851万美元，毛利率为75%，同比提升4个百分点[5] - 经营费用为5,570万美元，同比增加20%[6] - 净亏损为1,660万美元，每股亏损0.42美元[7] - 调整后EBITDA亏损110万美元，同比亏损减少67%[8] - 截至6月30日，现金及投资总额为1.862亿美元[8] 业务发展 - 公司专注于通过创新的TCAR技术减少中风风险和影响[10] 公司动态 - 公司宣布撤回2024年全年财务指引，原因是正与波士顿科学公司进行收购[9] 风险因素 - 公司面临的主要风险包括收购整合、市场竞争、经济环境和疫情等[12]

Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes through minimally invasive techniques SUNNYVALE, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Silk Road Medical, Inc. ("Silk Road") (NASDAQ:SILK), a leading minimally invasive medical device company focused on reducing the risk and impact of stroke, today announced the milestone that more than 100,000 TCAR procedures have been performed to date. Since its incepti ...

NEW YORK, July 29, 2024 /PRNewswire/ -- 1. Do you file class actions and go to Court? 2. When was the last time you recovered money for shareholders? 3. What cases did you recover money in and how much? Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America [email protected] Tel: (212) 971-1341 Click here for more information https://monteverdelaw.com/case/silk-road-medical-inc/. It is free and there is no cos ...

NEW YORK, July 19, 2024 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law may seek additional disclosures or other relief on behalf of the shareholders of these companies. Kuehn Law is investigating whether the Boards of the below companies 1) acted to maximize shareholder value, 2) failed to disclose material information, and 3) conducted a fair process: Silk Road Medical, Inc. has agreed to merge wi ...

Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court. Contact: Juan Monteverde, Esq. MONTEVERDE & ASSOCIATES PC The Empire State Building 350 Fifth Ave. Suite 4740 New York, NY 10118 United States of America jmonteverde@monteverdelaw.com Tel: (212) 971-1341 Attorney Advertising. (C) 2024 Monteverde & A ...